Introduction: overview of adipose tissue disturbances in HIV 1-associated lipodystrophy
The introduction of highly active anti-retroviral treatment (HAART), based on the administration of a combination of anti-retroviral drugs from different families, has had considerable success in improving the mortality and morbidity outcomes of HIV 1-infected patients. However, long-term treatment of HIV 1-infected patients can result in the appearance of several secondary effects, the most frequent being the so-called 'HIV-infection, HAART treatmentassociated lipodystrophy syndrome' (HALS). Despite recent improvements in the design of drug components of HAART that have reduced the occurrence of new cases in the Western world, the incidence of HALS has been estimated to be close to 50% of anti-retroviral-treated HIV 1-infected patients. Thus, after obesity, HALS is probably the second-most prevalent disease worldwide that involves primarily adipose tissue. The molecular basis of this syndrome is not fully understood, but intensive research in recent years has revealed multiple aspects of adipose tissue physiopathology that were previously unsuspected, and HALS research has highlighted novel aspects of adipose tissue that are highly relevant to other diseases such as obesity and lipodystrophies of genetic origin. Many available reviews cover the clinical aspects of HALS, 1, 2 extensive description of the cellular and molecular alterations associated with the syndrome 3 and its potential management. 4 The present review is focused specifically on summarizing how the information obtained from HALS research contributes to our knowledge of novel aspects of adipose tissue biology which may be relevant to obesity research. HAART treatment-associated lipodystrophy syndrome (HALS) is usually associated with peripheral fat wasting, central adiposity and, in some cases, lipomatosis, as well as systemic insulin resistance and hyperlipidemia. Not all these features of the syndrome necessarily appear together in the same affected individual and, whereas lipoatrophy is the most frequent alteration, lipomatosis appears in a small percentage of HIV 1-infected, HAART-treated patients.
Lipoatrophy usually involves the face, arms, legs and buttocks. Together with an increase in intra-abdominal adipose tissue, adipose tissue may also accumulate in the breasts as well as in the dorso-cervical area ('buffalo hump' pads). The systemic metabolic disturbances observed are usually hypercholesterolemia and hypertriglyceridemia, insulin resistance leading to type 2 diabetes and hyperlactatemia. With regard to the circulating adipokine levels, reduced serum adiponectin is common. 5 The results of several studies have led to the proposal that specific drug components of HAART are preferentially involved in particular aspects of the syndrome. For instance, several drugs of the nucleoside analog reverse transcriptase inhibitor (NRTI) family are especially prone to favoring lipoatrophy, whereas drugs of the protease inhibitor family have been proposed to be preferentially involved in visceral obesity and in the systemic lipid disturbances. However, no clear-cut delineation of these relationships has been possible, as it appears that the complexities of HAART combinations are themselves at least partially causative of the main symptoms of the syndrome. Thus, lipoatrophic adipose tissue appears to contribute also to systemic metabolic disturbances, as is already known to occur in animal models of lipoatrophy and in human lipoatrophies of genetic origin. 6 The action of anti-retroviral drugs in adipocytes confirms the involvement of master transcription factors in the control of adipocyte differentiation Many drugs from the distinct families used in HAART have been reported to alter the differentiation of adipocytes in cell culture (for review see 3). Protease inhibitors have been reported to impair adipocyte differentiation of murine cell lines (3T3L1, 3T3-F442A) and human adipocytes in primary culture. More recently, some NRTIs 7, 8 as well as efavirenz, a non-nucleoside analog reverse transcriptase inhibitor (NNRTI), 9 were also shown to impair adipocyte differentiation. The precise mechanisms of inhibition are not known, but they involve a pattern of alterations of gene regulation that is fully consistent with our current concepts of the role of the main regulatory effectors of adipogenesis. Thus, the action of anti-retroviral drugs impairing the acquisition of the mature adipocyte phenotype involves a downregulation of master genes of adipogenesis, such as CCAAT/enhancer binding protein-a (C/EBPa) and peroxisome-proliferator activated receptor g (PPARg). 3 Thus, impaired adipocyte differentiation may play a major role in HALS, especially as it may suppress the capacity of pre-adipocytes to replenish adipose depots when lipolytic and apoptotic events take place in adipocytes in association with lipoatrophy. Moreover, together with the action of HAART components, pro-inflammatory signals appearing in adipose tissue depots in HALS may contribute to the impairment in adipogenesis (see below). However, it should be noted that the treatment of patients with thiazolidinediones, drugs acting on PPARg and promoting adipocyte differentiation, has had poor success in alleviating HALS. 18 This indicates that, either treatment 'in vivo' does not fully restore adipocyte differentiation, or that impairment of adipogenesis plays only a minor role in the full development of HALS. However, the reduced expression of the receptor PPARg in adipose tissue from HALS patients 14, 17 may contribute to their lack of sensitivity to thiazolidinedione treatment.
HALS highlights the role of mitochondrial activity in white adipose tissue biology
Mitochondrial toxicity was among the first hypotheses regarding the causes of HALS. NRTIs are drugs that are present in HAART regime combinations, and are known to Similar findings were reported when a stavudine-based regime was replaced with a treatment containing protease inhibitors and efavirenz, an NNRTI less prone to causing mitochondrial toxicity. 22 Treatment of rat with the NRTI zidovudine causes mtDNA depletion and, moreover, several studies have indicated that anti-retroviral drugs that cause mtDNA depletion also impair adipocyte differentiation in cell culture, 7 and treatment of adipocyte cell cultures with uridine, which averts mitochondrial dysfunction, prevents NRTI-induced impairment in adipocyte differentiation 23 and ameliorates lipodystrophy 'in vivo'. 24 Therefore, extensive studies on mitochondria and HALS have demonstrated that mitochondrial disturbances in adipose tissue are capable of eliciting profound effects in adipose tissue biology and appear to promote lipoatrophy. However, recent data has also indicated that mitochondrial disturbances in HALS patients involve more wide-ranging events than mtDNA depletion alone, and mitochondrial dysfunction is not only attributable to NRTI toxicity but probably results from a complex interaction of HIV-1 infection-dependent events, including local inflammation together with the toxic effects of anti-retroviral drugs, as described below.
The role of mitochondrial function in white fat biology and in related human pathologies has traditionally been neglected, probably due to the low amounts of mitochondria in white adipocytes relative to those in brown adipocytes. Research on HALS, however, has contributed to a re-appraisal of the importance of mitochondria in this tissue. Studies by Corvera and collaborators 25 have revealed that mitochondrial biogenesis is essential for adipose tissue differentiation, and that mitochondrial remodeling in white fat is a key component of the metabolic response to insulin sensitizers such as rosiglitazone. Studies undertaking an analysis of mitochondria in adipose tissue from obese patients have been scarce. The expression of the master regulator of mitochondriogenesis, peroxisome proliferator-activated receptor-coactivator-1a (PGC-1a), has been reported to be reduced in adipose tissue from obese patients. 26 Other authors found a downregulation of expression of mitochondrial electron transport (OXPHOS) genes preferentially in visceral adipose tissue of obese patients developing type 2 diabetes. 27 In mice, weight gain has been associated with the downregulation of OXPHOS genes in visceral adipose tissue, 28 and in ob/ob mice, an animal model of obesity, there is reduced mtDNA in visceral adipose tissue. 29 Experimental modification of the respiratory chain system in adipose tissue through genetically-driven overexpression of mitochondrial uncoupling protein-1 (UCP1) in white adipose tissue protects mice from genetic or dietary-driven obesity, in association with enhanced mitochondrial biogenesis in white fat. 30, 31 Research on mitochondrial disturbances in adipose tissue from HALS patients has occurred during a period of mitochondrial research characterized by a dramatic expansion of the existing concepts of biological role of mitochondria. The mitochondrion had been, for years, considered to be simply the fuel provider for the most basic energy demands of the cell. However, mitochondria are now recognized as being critical components in the control of multiple key cellular processes, from apoptosis to the production of reactive oxygen species (ROS). For instance, mitochondrial by-products such as ROS impair the extent of adipocyte proliferation and differentiation, 32, 33 and a known consequence of impaired mitochondrial bioenergetics, such as that occurring in HALS, is an enhancement in ROS production. Several aspects of mitochondrial dysfunction present in adipose tissue from HALS patients, from abnormal respiratory chain activity due to mtDNA depletion to low levels of UCP2, a mitochondrial uncoupling protein involved in the control of ROS production, 17 may lead to permanent oxidative stress in adipose tissue. This may contribute to impaired adipocyte differentiation, inflammation and activation of apoptosis, as described below. In summary, mitochondrial alterations are evident in adipose tissue from HALS patients and there is also evidence of mitochondrial dysfunction in type 2 diabetes associated with obesity. 27, 34 However, it is also apparent that simple impairment of metabolic energy production by mitochondria in adipose tissue, which makes only a small contribution to overall energy expenditure, is not sufficient to explain the complexities of HALS or the overall metabolic syndrome associated with obesity. Recently recognized signaling properties of mitochondrial function for multiple aspects of adipocyte biology are likely to be the basis of these complex alterations, and mitochondrial activity could influence the myriad of adipokines and signaling molecules released by adipose tissue, thus influencing systemic metabolism. For instance, impaired mitochondrial ATP synthesis in adipocyte mitochondria may activate AMP-kinase, a regulatory signal impairing lipid accretion. 35, 36 A lowered NADH/NAD ratio may also activate Sirt1, a protein deacetylase controlling gene transcription and recently reported to impair adipocyte differentiation. 37 Finally, ROS are capable of inducing TNFa and interleukin-6 expression in adipocytes, 38 and it has recently been reported that the extent of mitochondrial ROS production by adipocytes is involved in the control of adiponectin release through changes in the levels of CHOP-10, 39 a transcription factor involved in mediating the action of ROS changes in the control of adipocyte differentiation. 33 This is consistent with the low adiponectin levels found in HALS patients 5 and also in some obese patients that are known to contribute to insulin resistance. 40 A summary of Lipodystrophy in HIV 1-infected patients F Villarroya et al the main alterations and potential mechanisms by which mitochondrial disturbances may contribute to HALS is shown in Figure 1 .
Lipomatosis in HALS reveals a potential for brown adipocyte differentiation and proliferation in adult humans
A particular disturbance appearing in a subset of patients of HIV-1 lipodystrophy is lipomatosis. It usually consists of progressively enlarged fat pads in the dorso-cervical region, so called 'buffalo humps'. 41, 42 This is a distinct phenomenon which develops in subcutaneous adipose tissue of a specific anatomical region, as opposed to visceral adipose tissue enlargement which is reminiscent of visceral obesity. In the 'buffalo hump', the adipocytes are small, and there is a heterogeneous pattern of lipid vacuole distribution in the cells, from multivacuolate to univacuolate. 43 Auto-transplantation of adipose tissue from the 'buffalo hump' to facial lipoatrophic areas in reconstructive surgery has been reported to result in some cases in the so-called 'hamster syndrome'; an enlargement of cheek adipose tissue, a former lipoatrophic area, as a consequence of the transplantation. 44 This indicates that cells in the lipomatous areas have acquired a highly proliferative capacity that persists even when they are placed in the environment of lipoatrophic areas.
Another feature of this growing adipose tissue is the expression of mitochondrial UCP1, the differential molecular marker of brown versus white adipocytes. 45 This feature, which does not occur in the subcutaneous lipoatrophic area, together with the morphological features of adipocytes in 'buffalo hump' pads is suggestive of the acquisition of brown-fat features in this lipomatous tissue. However, a more extensive analysis of molecular markers indicated that 'buffalo hump' tissue does not express a full-blown brown Figure 1 The figure depicts a summarized model of how alterations attributable to mitochondrial dysfunction caused by anti-retroviral drug treatment, HIV-1 and inflammatory signals may ultimately lead to lipoatrophy in the HIV-1 infection and HALS. HAART may act directly on mitochondria by causing mtDNA depletion due to inhibition of mtDNA polymerase-g and other mitochondrial alterations through distinct, and as yet unknown, mechanisms. HIV 1-encoded proteins may act directly on the mitochondrial machinery in control of apoptosis, that is, the MPTP. In addition, inflammatory signals may cause direct and indirect effects on mitochondria, altering gene expression of components of the oxidative phosphorylation (OXPHOS) system and the apoptotic machinery of mitochondria. An impaired OXPHOS system as well as lowered mitochondrial UCP2 may ultimately lead to enhanced production of reactive oxygen species (ROS). Mechanisms of intracellular signaling sensitive to enhanced oxidative stress and altered energy metabolism (AMP-kinase, Sirt1, CHOP-10 and others) may convey these alterations into changes in overall adipocyte function and gene expression thus leading to impaired adipocyte differentiation, altered release of regulatory adipokines and enhanced apoptosis. and may be associated with some intrinsic properties of brown adipocyte precursors to proliferate under physiopathological stimuli. In fact, brown adipose tissue in rodents is characterized by a capacity for dramatic enlargement, including cell proliferation, in response to external signals associated with thermogenic requirements. 48 Although the precise etiopathogenesis of this particular feature of HALS is unknown, the occurrence of a similar phenomenon of dorso-cervical lipomatosis and UCP1 expression in patients bearing genetic mutations in mtDNA 49, 50 supported the hypothesis of a common mitochondrial-toxicity origin. 51 However, how a mitochondrial disturbance elicited by drugs may result in lipoatrophic behavior in some anatomical sites but cause lipomatosis in others is not known. No particular drug component of HAART has been reported to be specifically associated with the appearance of lipomatosis rather than lipoatrophy, 52 and events such as mtDNA depletion occur similarly in lipoatrophic subcutaneous fat and dorso-cervical lipomas. 46 However, studies using cultured brown adipocytes exposed to anti-retroviral drugs revealed that some NRTIs such as stavudine cause abnormal induction of UCP1 gene expression, probably mimicking retinoid-dependent stimulatory pathways in the control of this gene. 53 Studies on the capacity of white adipose tissue in adult humans to undertake a 'brown fat-like' phenotype, similarly to the situation in mice after thermogenic stress, have attracted some attention in obesity research, as this could represent an ideal system for driving an energy-storing cell into an energy-burning cell. 54 17 This is associated also with increased TNFa gene expression in these patients. All these alterations as well as the induction of interleukin-6 expression are further enhanced in adipose tissue from patients with full-blown HALS. 17, 64 It appears therefore that HIV-1 infection initiates a first wave of alterations in adipose tissue which are amplified by HAART, and ultimately result in lipoatrophy. In fact, there is also evidence in HIV 1-infected patients without HAART of early metabolic alterations such as hypertriglyceridemia and altered levels of serum fatty acids.
65-67
The capacity of adipocytes to be infected by HIV-1 is a matter or controversy. Initial studies indicated the presence in adipocytes of all specific HIV-1 receptors and showed a weak, but apparent capacity of adipose cells to be infected. 68 However, the results of further studies led to a questioning of this possibility. 69, 70 More recently, it has been reported that human adipocytes in primary culture are susceptible to HIV-1 infection, and exposure to high levels of TNFa, as occurs in adipose tissue of HALS patients, leads to effective HIV-1 replication and production by adipocytes. 71 On the other hand, cellular components other than adipocytes that are present inside adipose tissue depots may also be the targets of HIV-1 infection. In this sense, macrophages, that play an important role in adipose tissue disturbances (see below) can be infected by the HIV-1 virus, 72 and this may have relevant consequences in their local environment through the release of multiple signaling molecules acting on adipocytes. Finally, regardless of the potential for infection of adipose tissue cells by HIV-1, it is well known that some of the proteins encoded by HIV-1, such as Vpr or Tat, are released into the systemic circulation and can have local or distal effects on non-infected cells. 73, 74 Although no studies have 76 Vpr is also a known inducer of apoptosis through activation of the mitochondrial permeability transition pore (MPTP) 77 and therefore may contribute to adipocyte apoptosis in HALS, although this issue has not yet been addressed in adipose cells. In summary, there are multiple lines of evidence that HIV-1 infection itself, regardless of HAART, may contribute to adipose tissue disturbances in HALS, either through direct HIV-1 infection of cells in adipose tissue or indirectly via the action of HIV 1-encoded proteins. This observation should be added to the growing evidence for the concept that viral infections may have important consequences in adipose tissue biology. In this sense, partial lipoatrophy has been described in association with hepatitis B infection, 78 and coinfection with the hepatitis C virus favors lipoatrophy and metabolic disturbances in HIV 1-infected patients. 79, 80 The concept that adipose tissue biology may be susceptible to viral infections has been extensively examined in relation to the role that human adenovirus-36 and perhaps other adenoviruses may have in promoting obesity. 81, 82 Adenovirus-36 increases adipocyte differentiation of 3T3-L1 cells and human adipocytes, 83, 84 and antibodies against adenovirus-36 are high in obese patients, 81 and thus it has been
proposed that such viral infection may play an important role in the development of obesity. It is interesting to note that the effects of infection by viruses from such different families as adenoviruses and retroviruses could contribute to distinct adipose tissue disturbances in humans, from obesity to HALS. In any case, the involvement of distinct viral infections in adipose tissue disturbances is likely to constitute a growing research issue in the coming years, especially in interplay with the well-established role of local inflammation in adipose tissue disturbances in obese and HALS patients.
The paradox of the common inflammation status in adipose tissue from obese and HALS patients
One of the recent achievements in HALS research has been the recognition of a local inflammatory status at least in atrophic subcutaneous adipose tissue from affected patients. 92 or with the action of viral proteins. 93 For instance, Tat is capable of inducing the release from endothelial cells of monocyte chemoattractant protein-1 (MCP-1, also known as CCL-2), a chemokine produced also by macrophages and to minor extent by adipocytes, which favors the recruitment of macrophages. 94 HAART may also contribute to endothelial cell changes and macrophage recruitment by increasing MCP-1 release. 93 Recruitment of macrophages enhances the inflammatory signaling inside the tissue and, in fact, it is known that activated macrophages play a predominant role in the production of cytokines and MCP-1 in adipose tissue. 95 Many of these signaling agents act in concert to elicit the pro-inflammatory changes in adipose tissue. For instance, Tat and TNFa, act synergistically in the induction of interleukin-6 release by endothelial cells 93 whereas some anti-retroviral drugs potentiate the apoptotic action of TNFa. 96 In summary, it is expected that the effect of inflammatory cytokines of distinct cellular origin inside the adipose depots would be a reduction in the adipose tissue mass favored by lipolytic effects and insulin resistance. The number of adipose cells may be reduced by a combination of apoptosis and impaired adipocyte replenishment due to the concerted inhibitory action of cytokines such as TNFa, and HAART on adipocyte differentiation. In recent years, it has been established that obesity is associated with a low-grade inflammatory status involving enhanced levels of pro-inflammatory signals in adipose tissue depots of obese patients. Key metabolic disturbances associated with obesity such as insulin resistance appear to be closely linked to the presence of this diffuse inflammatory status in adipose tissue, which results in abnormal release of cytokines and adipokines and thus ultimately influences 97 and various other inflammatory mediators and cytokines have also been identified as being overexpressed in adipose tissue from obese patients (such as interleukin-6, for instance). 98 Macrophage infiltration has also been described in adipose tissue of obese patients 99, 100 and the action of enhanced MCP-1 levels appears to be among the primary events eliciting the whole pro-inflammatory process in adipose tissue associated with obesity. 101 What is the resolution to apparent paradox of a common inflammation status in adipose tissue associated with such opposite conditions of adipose tissue as obesity and lipoatrophy? In obesity, it has been suggested that it is the expansion of adipocytes (and locally related events such as hypoxia or other as yet unknown signals) that causes the production of chemotactin signals by adipocytes themselves, pre-adipocytes or even resident macrophages, thus leading to massive macrophage recruitment. 102, 103 The scenario in lipoatrophic adipose tissue in HALS patients would be similar in terms of the effects but would be distinct in its origin: here, HIV-1 infection plus anti-retroviral treatment elicits the macrophage recruitment process and overall inflammation in adipose tissue, thus promoting adipose wasting and apoptosis. The inflammatory process common to obesity and HALS, therefore, supports the notion that the inflammatory process in obesity is not a cause of adipose tissue enlargement but is a biological reaction attempting to limit the excess of such expansion, but which does not succeed due to the net gain in energy leading to fat accumulation. The inflammatory process occurring in adipose tissue of obese patients has been specifically associated with insulin resistance. 102 The strong similarity in the inflammatory processes occurring in hypertrophic and atrophic adipose tissue from obese and lipodystrophic patients, respectively, supports the notion that, regardless of the amounts of fat, the inflammation in adipose depots leads to insulin-resistant processes that are effectively common to the obese and lipodystrophic patients. In this sense, the increase in systemic cytokines as well as the altered release of adipokines (for instance, reduced adiponectin levels) elicited by inflammatory signals occur both in obese and HALS patients and can be seen to be responsible for some of the metabolic alterations common to both pathologies, such as insulin resistance.
Increased lipolysis and free fatty acid levels, another feature common to obesity and HALS Together with overall hyperlipidemia, HALS is associated with increased levels of circulating non-esterified, free fatty acids (FFAs) . 104 This appears to be due to enhanced lipolysis in adipose tissue, an expected event considering the progressive loss of fat in lipoatrophic adipose depots. The increased levels of FFAs play an important role in the insulin resistance appearing in HALS, and lipolysis inhibition attained through pharmacological means has been reported to ameliorate insulin sensitivity in HALS patients. 105 Similarly to other events already mentioned, activation of lipolysis appears to be due to a complex combination of HIV-1 infection and HAART-mediated events. In fact, enhanced lipolysis has been reported in HIV 1-infected patients irrespective of HAART. 67 Anti-retroviral drugs of the protease inhibitor family activate lipolysis in adipocytes in cell culture, 106, 107 and discontinuation of treatment with this type of drugs has been shown to reduce lipolytic activation and FFA levels in patients. 108 Either in relation to HIV-1 infection itself or to HAART, the increase in TNFa and other cytokines in adipose tissue may play a major role in the sustained increase in lipolysis. TNFa, like other cytokines such as interleukin-6, 109 activates lipolysis in adipocytes 110 and has been directly implicated in the increased release of fatty acids from adipose tissue in HALS patients. 111 Moreover, co-culture of adipocytes and macrophages indicates that FFAs released by adipose cells activate TNFa release by macrophages, thus indicating a positive cross-talk between adipocytes and macrophages involving mainly FFA and TNFa release, respectively.
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As recently reviewed, excess lipolysis and increased levels of circulating FFAs are commonly observed in obesity. 113 This abnormality is considered to be the cause of at least some of the metabolic defects (dyslipidemia, insulin resistance) associated with obesity, and high FFA levels are involved in multiple metabolic alterations, from impaired insulin action in muscle to lipotoxicity in pancreatic b-cells. Like in HALS, the high local levels of TNFa and other cytokines are considered to contribute to enhanced plasma FFA levels in obesity. 114 Thus, the rise in circulating FFA levels appears to be another common event contributing to the metabolic syndrome present both in HALS and obesity.
Apoptosis, a key biological process in adipose tissue as revealed by HALS
Reports of apoptosis in adipose tissue are relatively scarce. 115 This is probably due to the fact that biological pathways leading to adipocyte cell death and potential adipose tissue depletion are not expected to play a causative role in obesity, the disease inspiring most of the adipocyte biology research. However, it is known that apoptosis can occur in cell types that compose adipose tissue depots, including mature adipocytes. However, as for other specialized mammalian cells, differentiation of pre-adipocytes into adipocytes is associated with a relative resistance to apoptosis. A number of agents have been reported to experimentally induce the apoptosis in adipocytes, from inflammatory cytokines such as TNFa, 116 to flavonoids and polyunsaturated fatty acids. 117, 118 Lipodystrophy in HIV 1-infected patients F Villarroya et al A common feature appearing in subcutaneous adipose tissue of HALS patients is activation of apoptosis in adipocytes as well as in endothelial cells of adipose depots. 64, 89, 96 HAART components appear to differentially influence the extent of apoptosis in adipose depots of HALS patients. Increased levels of apoptosis along with mtDNA depletion occur in adipose tissue of patients treated with the NRTI stavudine, relative to uninfected controls, 21 and switching the patients from stavudine to other NRTIs such as abacavir or zidovudine leads to a significant improvement in mtDNA levels and also in adipocyte apoptosis. 21 The role of anti-retroviral drugs other than NRTIs on adipocyte apoptosis is unclear. It has been reported that nelfinavir (and perhaps other protease inhibitors) protects against apoptosis through direct interaction with the MPTP complex, which controls mitochondria-driven apoptosis. 119 Although these studies have not been carried out in the context of adipose cells, they would not support a role for protease inhibitors as substantial contributors to promotion of adipose tissue apoptosis. However, recent data from cultured adipocytes indicate that nelfinavir favors apoptosis.
120
The re-assessment of the importance of mitochondrial activity in adipocyte biology described above should be extended to mitochondrial-mediated apoptotic pathways. Studies from HALS patients revealed altered mitochondrial morphology in adipocytes undergoing apoptosis. 121 Moreover, switching anti-retroviral treatment to drugs known to result in minor mitochondrial toxicity is associated with reduced adipose tissue apoptosis and increased fat mass in the subcutaneous area. 21 Other changes in the anti-retroviral regime that improve the overall metabolic pattern but do not affect mitochondrial toxicity do not ameliorate apoptosis in adipose tissue. 122 Thus, studies in HALS support a proposal that mitochondrial-mediated alterations are capable of eliciting activation of apoptosis in adipocytes, as is already known for other cell types. In fact, as mentioned above, one of the hypotheses of how mitochondrial impairment may lead to enhanced adipose catabolism involves AMP-kinase activation due to a rise in AMP levels, 123 and, recently, AMPkinase activation has been reported to induce apoptosis in adipocytes. 124 Another possibility for activation of adipocyte apoptosis originating in mitochondria could involve ROS production, and recent studies using anti-retroviral drugs of the protease inhibitor family have shown increased apoptosis in adipocytes in culture due to enhanced oxidative stress. 125 The possibility that active apoptosis in adipose tissue may lead to a reduction in body weight has been demonstrated in experimental models such as transgenic mice overexpressing caspase-8 in adipose tissue. 126 However, lipoatrophy in subcutaneous adipose tissue of HALS patients is probably the more evident example that enhanced apoptosis in adipose tissue may be associated with reduced fat mass in humans, and, as mentioned above, changes in the antiretroviral composition of HAART that minimize adipose tissue apoptosis are associated with an improvement in fat mass in the subcutaneous area. In this situation, the increased levels of TNFa, and other cytokines associated with an enhanced inflammatory status, are considered to be the main inducers of apoptosis in adipose tissue. Other factors known to enhance apoptosis in adipose tissue such as increased levels of interferon-a 127 due to viral infection or the above-mentioned activation of AMP-kinase activity, as a consequence of intracellular energy depletion may also play a role, although the relative contribution of these pathways has not been specifically addressed.
Is there altered apoptosis in adipose tissue of obese patients? There is limited date providing, surprisingly, the evidence of some extent of adipocyte cell death in adipose depots of obese patients and obese mice animal models, although it has been claimed that the morphological features are more indicative of necrosis than apoptosis. 128 Moreover, infiltrating macrophages in adipose tissue of obese mice and humans have been reported to be localized to dead adipocytes and to scavenge residual 'free' adipocyte lipid droplets. 128 It is obvious that, in obesity, cell death events in adipose tissue do not have a massive consequence in reducing the amounts of adipose tissue. Similarly, to overall response to inflammation mentioned above, it is possible that a positive metabolic energy balance in adipose depots may overcome the inflammation-mediated activation of catabolic pathways and even apoptosis. However, adipocyte death appears to be an important component of the events associated with the obesity-associated and lipodystrophyassociated macrophage recruitment in adipose tissue, and may have common systemic consequences (adipokine release or other) regardless of any consequence in overall fat mass.
The heterogeneity of visceral and subcutaneous adipose tissue: more evidence from HALS The substantial differences in the biology of adipose tissue depots, especially between subcutaneous and visceral adipose tissue, and their differential influence on the overall pathological consequences of obesity are well established. HALS provides dramatic evidence of such concept. Thus, in contrast to obesity, in which both types of depots are usually enlarged to a greater or lesser extent, HALS is characterized by distinct and often opposite behavior of each depot type, as subcutaneous adipose tissue is often atrophied whereas visceral adipose tissue may be enlarged. This differential behavior has been related to distinct components of the HAART regime: inhibitors of reverse transcriptase for subcutaneous lipoatrophy and inhibitors of protease for visceral obesity. This has been supported by studies attributing to protease inhibitors most of the systemic metabolic syndrome associated with HALS which is in agreement with the current concept that accumulation of visceral abdominal adipose There is considerable knowledge of the metabolic differences between visceral and subcutaneous adipose tissue depots. Multiple differential aspects, from their sensitivity to insulin-mediated control of lipolysis to their capacity for adipokine release, have been extensively reviewed. 130 The etiopathology of HALS, in which mitochondrial toxicity, HIV-1 infection, inflammation, enhanced lipolysis and insulin resistance appear as the main events suspected to cause the syndrome, points out to the possibility that distinct adipose tissue depots show differential responsiveness to these factors. However, reports of extensive studies of regional differences between visceral and subcutaneous adipose depots for most of these aspects are scarce. A few studies in rodents indicated remarkable depot-specific differences in mitochondrial activity, 131 whereas others reported no changes in mitochondrial mass and in thiazolidinedionemediated mitochondrial biogenesis between visceral and subcutaneous adipose tissues. 57 Recently, it has been reported that treatment of rats with the NRTI zidovudine causes mtDNA depletion and impaired mitochondrial oxidative activity in subcutaneous adipose tissue but not in visceral fat. 132 However, no reports of systematic comparative studies of the mitochondrial machinery between subcutaneous and visceral adipose tissue in humans are currently available. Concerning inflammation and the associated macrophage recruitment, it has been reported that interleukin-6, interleukin-18 and MCP-1 [133] [134] [135] are more highly expressed in visceral than in subcutaneous adipose tissue whereas this has not been observed for TNFa. 136 The fact that highest expression of pro-inflammatory chemokines and cytokines is in the visceral depots has been proposed to be due not to intrinsic differences in the capacity of adipocytes to produce some of these molecules, but to the preferential presence of infiltrating macrophages and other non-adipose cells in the visceral depot. 95 Concerning lipolysis, it is known that in healthy individuals, FFAs released from the visceral fat depot have a lower contribution to systemic FFA delivery relative to those from subcutaneous adipose tissue 113 and that visceral fat is not the predominant source of excess systemic FFAs in obese subjects. 130 Thus, whereas the high cytokine expression in visceral depots may contribute to the systemic effects observed in HALS associated with visceral adipose accumulation, the high lipolysis in subcutaneous adipose tissue of 
Conclusions
In summary, HALS research in recent years has confirmed some of our current concepts of the cellular and molecular basis of adipose tissue biology and its disturbances, and at the same time it has revealed novel aspects of adipose tissue biology with a potential impact on obesity research and treatment. A summary of common features of the etiopathogenesis of HALS and obesity is shown in Figure 2 . Future possible research inspired by HALS studies ranges from further establishing the role of viral infections in adipose tissue biology, to determining the actual role of mitochondrial disturbances in adipose tissue and identifying the molecular mechanisms responsible for signaling intracellular bioenergetic changes into alterations in adipocyte differentiation, apoptosis or adipokine release. Concerning therapy-orientated research, it is evident that therapeutic strategies aimed at combating obesity on the basis of reversing the positive energy balance would not be likely strategies for alleviating HALS. However, strategies aiming to prevent the negative effects of obesity on the metabolic syndrome, or on cardiovascular diseases, may profit from the identification of pro-inflammatory signaling as a common alteration in adipose tissue of obese and HALS patients. According to HALS research, promoting adipocyte cell death as a potential strategy for reducing the fat mass comes with the clear inconvenience of concomitant activation of macrophage recruitment and enhancement of the inflammatory-mediated disturbances. As final consideration, it is worth highlighting that in recent years HALS research has resulted in the accumulation of a large bulk of information on adipose tissue. This has happened in the context of HIV-1 infection and treatmentrelated studies, a research field formerly somewhat distant from that of obesity, which has traditionally inspired most adipose tissue research. Promotion of common forums of communication between researchers in these two areas will undoubtedly result in advancement in the knowledge of adipose tissue physio-pathology relevant to both diseases, and ultimately in the design of successful treatment and/or prevention strategies.
